Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefotiam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.99 |
| ▸ | LMNA | P02545 | 3/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.57 |
| ▸ | PGR | P06401 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.51 |
| ▸ | SLC22A8 | Q8TCC7 | 3/20 | 0.51 |
| ▸ | SLC22A11 | Q9NSA0 | 3/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefotiam SCHEMBL193845 | 1.00 | L3MBTL1 (1.00) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL10899868 | 1.00 | L3MBTL1 (1.00) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL11065530 | 1.00 | L3MBTL1 (1.00) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL28031009 | 0.99 | L3MBTL1 (0.99) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL20528733 | 0.99 | L3MBTL1 (0.99) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL27968324 | 0.99 | L3MBTL1 (0.99) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL27849044 | 0.99 | L3MBTL1 (0.99) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL27715723 | 0.99 | L3MBTL1 (0.99) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL28264248 | 0.99 | L3MBTL1 (0.99) | L3MBTL1TDP1LMNAHSD17B10NR1I2 | |
| Cefotiam SCHEMBL28028493 | 0.99 | L3MBTL1 (0.99) | L3MBTL1TDP1LMNAHSD17B10NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1829 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| CN-112739307-B | Infusion system | 吴制药有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-221772016-U | Mixing equipment for cefotiam hydrochloride production for injection | 深圳立健药业有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-112986471-B | Detection method of cefotiam hydrochloride related substances for injection | 重庆圣华曦药业股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| CN-114136941-B | SARM1 enzyme inhibitor and screening method and application thereof | 北京大学深圳研究生院 | 2024-04-16 | — | — | CN | claimed |
| CN-117630223-A | Cefotiam hydrochloride polymer analysis method for injection | 哈药集团技术中心 | 2024-03-01 | — | — | CN | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| US-11376194-B2 | Infusion system | OH PHARMACEUTICAL CO., LTD. (US) | 2022-07-05 | — | — | US | claimed |
| EP-1618894-A1 | COMPOSITION FOR INJECTION | Takeda Pharmaceutical Company Limited (JP) | 2006-01-25 | — | — | EP | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| CN-1181072-C | Process for the preparation of basic anti-biotic-inorganic acid and intermediate oxalates | ������������ʽ���� | 2004-12-22 | — | — | CN | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-6642377-B1 | Subjecting oxalate to salt exchange with alkali earth metal salt | EISAI CO., LTD. (JP) | 2003-11-04 | — | — | US | claimed |
| CN-1365362-A | Process for the preparation of basic anti-biotic-inorganic acid and intermediate oxalates | EISAI CO LTD (JP) | 2002-08-21 | — | — | CN | claimed |
| EP-1201665-A1 | PROCESS FOR THE PREPARATION OF BASIC ANTIBIOTIC-INORGANIC ACID ADDITION SALTS AND INTERMEDIATE OXALATES | Eisai Co., Ltd. (JP) | 2002-05-02 | — | — | EP | claimed |
| US-6245735-B1 | CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2001-06-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | L3MBTL1 389/4885TDP1 1276/4885LMNA 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.